Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020;21(1):1-3.
doi: 10.1080/15384047.2019.1665395. Epub 2019 Sep 18.

Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

Martina A Knechel  1 , Keith T Schmidt  2 , William D Figg  1   2
Affiliations
Comment

Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

Martina A Knechel et al. Cancer Biol Ther. 2020.

Abstract

ERA 223, a phase III, international, multicenter, double-blind study published in Lancet Oncology, was the first randomized controlled trial to investigate combined radium-223 (Ra-223) and abiraterone acetate plus prednisone or prednisolone (AAP) therapy. The data from ERA 223 demonstrated no increase in efficacy for this combination over AAP alone, and instead identified a significant safety concern due to the higher risk of fracture in the co-treatment group. The surprising results of this trial likely stem from the compounding osteoporotic effects of the different treatments, particularly the addition of prednisone, and supplementing therapy regimens with osteoprotective agents may aid in mitigating this safety risk.

Keywords: Abiraterone; denosumab; fracture risk; mCRPC; prednisone; radium-223.

PubMed Disclaimer

Comment on

References

    1. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M.. 2016. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 5:182–191. doi:10.1002/cam4.576. - DOI - PMC - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. doi:10.1056/NEJMoa1014618. - DOI - PMC - PubMed
    1. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. 2013. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369:213–223. doi:10.1056/NEJMoa1213755. - DOI - PubMed
    1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. doi:10.1056/NEJMoa1207506. - DOI - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 376:1147–1154. doi:10.1016/S0140-6736(10)61389-X. - DOI - PubMed

Publication types

LinkOut - more resources